Study Finds that AI Model Can Help Optimize Ovulation Trigger Injection Timing to Improve Outcomes for IVF Patients

Retrospective results show that over half of IVF cycles had possible early or late trigger injections, impacting egg retrieval outcomes.

SAN FRANCISCO, May 16, 2022 /PRNewswire/ -- A study led by researchers at Alife Health, a fertility technology company building artificial intelligence (AI) tools designed to improve in-vitro fertilization (IVF) outcomes, found that an interpretable machine learning model can help doctors optimize ovulation trigger injection timing to improve patient outcomes for a significant number of patients.

When undergoing IVF, patients are prescribed fertility medications to stimulate the ovaries to produce multiple eggs, or oocytes. In this process, physicians make a series of decisions that are critical to the outcome of the cycle. One of the most important decisions is when to give the final trigger injection to induce maturation of the oocytes. Triggering too early may not allow the oocytes to reach maturity, while triggering too late may result in post-mature oocytes – both decreasing chances of successful fertilization and creation of healthy embryos to use in IVF pregnancy.  

The study, published online in Fertility and Sterility, is one of the first to develop an interpretable machine learning model for helping clinicians optimize the day of trigger during ovarian stimulation. For their analysis, conducted with collaborators at RMA New York, Boston IVF, RSC Bay Area, and UCSF, the researchers drew from over 30,000 historical IVF cycles that were performed at multiple centers during 2014 and 2020.

Study results indicate that Alife's machine learning model could help doctors retrieve up to two to three more mature oocytes (eggs), two more fertilized oocytes (eggs fertilized by sperm), and one more usable blastocyst (embryo) on average. The findings not only confirm previously reported results, but do so across multiple different clinics and with a much larger sample size. The authors note that the study has limitations, the primary of which is its retrospective nature.

"Our results indicate that meaningful improvements in outcomes could potentially be achieved for a large percentage of ovarian stimulation cycles by using this model to assist with trigger injection timing," says the study's senior author, Kevin Loewke, head of data science at Alife. "We look forward to entering the clinic and performing prospective studies in the near future to confirm these retrospective findings."

"These promising results further indicate that we are on the right path towards utilizing AI to improve the effectiveness of IVF for our patients," says the study's co-author, Eduardo Hariton, MD, MBA. "As we aim to leverage technology to not only improve the outcomes for our patients, but also increase the efficiency of our providers and expand access to care, clinical decision support tools like this one will be crucial."

The study, titled "An interpretable machine learning model for predicting the optimal day of trigger during ovarian stimulation," was led by Michael Fanton, PhD, senior data scientist at Alife and co-authored by:

• Paxton Maeder-York, MS, MBA, CEO of Alife Health
• Eduardo Hariton, MD, MBA, reproductive endocrinology and infertility fellow at UCSF Center for Reproductive Health, joining RSC Bay Area later this year
• Oleksii Barash, PhD, HCLD, IVF laboratory director at RSC Bay Area
• Louis Weckstein, MD, reproductive endocrinologist at RSC Bay Area
• Denny Sakkas, PhD, CSO of Boston IVF
• Alan Copperman, MD, FACOG, reproductive endocrinologist at RMA New York
• Kevin Loewke, PhD, head of data science at Alife Health

ABOUT ALIFE HEALTH
Alife's mission is to modernize and personalize the IVF process with cutting edge artificial intelligence technology to improve outcomes and care for all. The company has built a consortium of partnerships with the top clinics and most renowned physicians to bring significant clinical improvements to patients globally. Founded by Paxton Maeder-York in 2020, the company is based in San Francisco and backed by top tier venture capital investors including Lux Capital, Union Square Ventures, and Maveron. To learn more visit www.alifehealth.com.

PRESS CONTACT
Jamie Gray, [email protected]

SOURCE Alife Health